Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with fabry disease

Journal of the American Society of Nephrology

Volumn 18, Issue 5, 2007, Pages 1547-1557

  Germain, Dominique P ^a   Waldek, Stephen ^b   Banikazemi, Maryam ^c,l   Bushinsky, David A ^d   Charrow, Joel ^e   Desnick, Robert J ^c   Lee, Philip ^f   Loew, Thomas ^g   Vedder, Anouk C ^h   Abichandani, Rekha ⁱ   Wilcox, William R ^j   Guffon, Nathalie ^k  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ GENZYME CORPORATION   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k EDOUARD HERRIOT HOSPITAL   (France)

^l NEW YORK UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENDOTHELIUM CELL; ENZYME DEFICIENCY; ENZYME THERAPY; FABRY DISEASE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; MITRAL VALVE REGURGITATION; MYALGIA; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RHINITIS; RIGOR; SEPSIS; SIDE EFFECT; SOMNOLENCE; STROKE; TACHYCARDIA; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 34248190164     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006080816     Document Type: Article

References (18)

1. Barth P: Disorders of sphingolipid metabolism. In: Inborn Metabolic Diseases, edited by Fernandes J, Saudubray J-M, Van den Berghe G, New York, Springer, 2000, pp 401-412
2. Desnick R, Ioannou Y, Eng C: Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver C, Sly W, Childs B, Beaudet A, Valle D, Kirtzler A, Vogelstein B, New York, McGraw Hill, 2001, pp 3733-3774
3. Desnick RJ: Enzyme replacement therapy for Fabry disease: Lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4: 1167-1176, 2004
4. Deegan P, Baehner AF, Barba-Romero MA, Hughes D, Kampmann C, Beck M: Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43: 347-352, 2006
5. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M: Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40: 1668-1674, 2002
6. Germain DP: Fabry disease: Recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 11: 1467-1476, 2002
7. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722, 2001
8. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001
9. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74, 2004
10. Ware J Jr, Snow K, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide, Boston, New England Medical Center Health Institute, 1993
11. Melzack R: The short-form McGill Pain Questionnaire. Pain 30: 191-197,1987
12. Levey AS, Greene T, Kusek JW, Beck GJ; MDRD Study Group: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155A, 2000
13. World Health Organization Adverse Reaction Terminology (WHO-ART). Uppsala, Sweden, WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, 1993. Available at: http://www.umc-products.com/ DynPage.aspx?id=4918&mn=1107
14. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946, 2002
15. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M: Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122: 900-908, 2004
16. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin HA 3rd, Kopp JB: Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138, 2002
17. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT: Patients with Fabry disease on dialysis in the United States. Kidney Int 61: 249-255, 2002
18. Banikazemi M, Bultas J, Waldek S, Wilcox W, Whitley C, McDonald M, Finkel R, Packman S, Bichet D, Warnock D, Desnick R, Fabry Disease Clinical Trial Study Group: Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 146: 142-144, 2007